Article
Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options.
Clinical lymphoma, myeloma & leukemia - 1 Oct 2013
Jabbour Elias J, Cortes Jorge E, Kantarjian Hagop M
Abstract excerpt
The development of tyrosine kinase inhibitors (TKIs) has led to extended lifespans for many patients with chronic myelogenous leukemia (CML). However, 20% to 30% of patients fail to respond, respond suboptimally, or experience disease relapse after treatment with imatinib. A key factor is drug resistance. The molecular mechanisms implicated in this resistance include those that involve upregulation or mutation of...
Topics
Join the communities discussing this publication.